Avenra is developing first-in-class phytoceutical drugs to target treatment of mild cognitive impairment -- delivering therapy before decline starts.

Complex diseases like cognitive impairment are treated after symptoms start. 

What if we could treat it early?

Avenra is at the forefront of answering this question.  We aim to provide FDA-approved solutions that aren't supplements and aren't traditional drugs. This isn't a supplement.   It's not "food as medicine".  It's a new class of FDA-approved drug that's revolutionizing healthcare.